HIV‐Transmission or Death at 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes HIV‐Transmission or Death at 7 Months compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Infant Grade 3/4 Severe Adverse Events at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes infant Grade 3/4 Severe Adverse Events at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Prematurity · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes prematurity compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Mother to Child Transmission at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Infant Mortality at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (moderate certainty).
1 finding from 1 review
Mother to Child Transmission at 1 Month · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at 1 Month compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Mother to Child Transmission Cumulative by 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission Cumulative by 7 Months compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Hepatotoxicity:13 Grade 3 and 4 toxicity · HIV‐infected pregnant women
Marazzi: AZT/3TC/NVP for HIV Infection in Pregnant Women With CD4 <250 showed no clear difference in maternal Grade 3/4 Hepatotoxicity compared with >250 cells/mm3; GRADE not reported.
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐1 Infected Pregnant Women Who Have CD4>200 Compared with Those Who Have CD4<200 Cells/mm3
It is very uncertain whether phanuphak: AZT/3TC/NVP (PMTCT) changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (ART) (very low certainty).
1 finding from 1 review
Infant Mortality at 12 months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Infant Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Prematurity · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes prematurity compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Low birthweight · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in low Birth Weight compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Stillbirth · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in stillbirths compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Death during study period · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in all‐cause mortality (prophylactic trials) (over duration of trial) compared with control/placebo (low certainty).
2 findings from 1 review
Safety of MSC infusion · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
1 finding from 1 review
Health‐related quality of life · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse of malignant disease (prophylactic trials) (>12‐month · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in relapse of malignant disease (prophylactic trials) (>12‐month compared with control/placebo (low certainty).
1 finding from 1 review
Incidence of acute GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in incidence of acute GvHD (prophylactic trials) compared with control/placebo (low certainty).
1 finding from 1 review